Research programme: T-cell adoptive immunotherapy - Cellectis

Drug Profile

Research programme: T-cell adoptive immunotherapy - Cellectis

Alternative Names: UCART 123; UCART 22; UCART 38; UCART CS1

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Cellectis
  • Developer Cellectis; Pfizer; Servier; University College London
  • Class CAR-T cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Multiple myeloma; Solid tumours

Most Recent Events

  • 03 Jan 2017 Cellectis files an IND application with the US FDA for Acute myeloid leukemia and Blastic plasmacytoid dendritic cell neoplasm
  • 15 Dec 2016 Recombinant DNA Advisory Committee approves two phase I study protocols of UCART 123 in Acute myeloid leukaemia and Blastic plasmacytoid dendritic cell neoplasm
  • 03 Dec 2016 Pharmacodynamics data from preclinical studies in Acute myeloid leukaemia (Blastic plasmacytoid dendritic cell neoplasm) presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH - 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top